TB Clinical Trials Conducted in China: The History and Future of the Beijing Tuberculosis and Thoracic Tumor Research Institute

2017 ◽  
pp. 303-318
Author(s):  
Lizhen Zhu ◽  
Mengqiu Gao
Keyword(s):  
Clinical Trials ◽  
Tumor Research ◽  
Research Institute

scholarly journals COT-11 EFFECT OF PHYSICIAN SUPPORTS ON QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL BRAIN TUMOR RESEARCH

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii42-ii42
Author(s):  
Keiko Furukawa ◽  
Yoshiki Arakawa ◽  
Yohei Mineharu ◽  
Masahiro Tanji ◽  
Akifumi Takaori ◽  
...  
Keyword(s):  
Quality Control ◽  
Clinical Trials ◽  
Quality Assurance ◽  
Brain Tumor ◽  
Ethical Review ◽  
Evaluation Score ◽  
Periodic Monitoring ◽  
Tumor Research ◽  
Brain Tumor Research ◽  
Physician Support

Abstract BACKGROUND Clinical physicians have difficulties in conducting investigator-initiated-trials because of increasing clinical duties in Japan. Therefore, physician support can be one of the important factors for quality control and quality assurance. In Kyoto University Hospital, clinical research professional’s support for physician had started at November 2012. In this study, we evaluate effect of physician supports on quality control and quality assurance in clinical brain tumor research. METHODS Our department of Neurosurgery has been a member of Brain Tumor Study Group in Japan Clinical Oncology Group (JCOG) since 2007. The number of registered patients, the status of periodic monitoring, the occurrence of inquiries per case, and details of physicians’ support (items, frequency, methods, etc.) in each clinical trial were investigated. The factors affecting the audit results conducted by JCOG Audit Committee on January 2013 and February 2019 are examined. RESULTS There are seven trials have been ongoing on or started since November 2012. There are fifty patients registered in the clinical studies until July 2019. Periodic monitoring has been carried out in 214 patients of cumulative total number since 2012. Physicians’ support mainly involved the preparation of ethical review documents, CRF documentation, responses to data queries, preparation of SAE reports, study schedule check and monitoring of observation items. The audit results of site visit were acceptable, total evaluation score 68.80 on January 2013 and excellent, total evaluation score 99.9 on February 2019. CONCLUSION Clinical Trials Act has been implemented, and further improvement in the quality of clinical trials has been demanded. As the results of this study, we clarified the necessity for physician support and the contribution to quality improvement.

scholarly journals Advances in adrenal tumors 2018

2018 ◽  
Vol 25 (7) ◽  
pp. R405-R420 ◽  
Author(s):  
J Crona ◽  
F Beuschlein ◽  
K Pacak ◽  
B Skogseid
Keyword(s):  
Clinical Trials ◽  
Translational Research ◽  
Adrenal Tumor ◽  
Clinical Care ◽  
Scientific Field ◽  
Adrenal Tumors ◽  
Recent Advances ◽  
Future Success ◽  
Tumor Research

This review aims to provide clinicians and researchers with a condensed update on the most important studies in the field during 2017. We present the academic output measured by active clinical trials and peer-reviewed published manuscripts. The most important and contributory manuscripts were summarized for each diagnostic entity, with a particular focus on manuscripts that describe translational research that have the potential to improve clinical care. Finally, we highlight the importance of collaborations in adrenal tumor research, which allowed for these recent advances and provide structures for future success in this scientific field.

scholarly journals The results of combined immunotherapy in integrated treatment of patients with malignant brain glioma

2008 ◽  
Vol 7 (5-2) ◽  
pp. 411-414
Author(s):  
V. V. Stupak ◽  
Ye. R. Chernykh ◽  
I. V. Pendyurin ◽  
O. Yu. Leplina ◽  
S. V. Mishinov
Keyword(s):  
Clinical Trials ◽  
Malignant Glioma ◽  
Integrated Treatment ◽  
Brain Glioma ◽  
Cytotoxic Cells ◽  
New Approaches ◽  
Complex Therapy ◽  
Combined Immunotherapy ◽  
Research Institute

The problem of search and development of new approaches to integrated treatment of patients with malignant brain glioma remain one of the most urgent issues for contemporary neurosurgery and neurooncology. In spite of the applied efforts the results of a complex therapy for malignant glioma, especially for glioblastoma, are utterly unsatisfactory. Immunotherapy is one of the directions searching for a generation of cytotoxic cells able to lyse the tumor. Combination of various immunotherapeutic approaches is regarded the most perspective way. Since 1999 Neurosurgical Clinic of Novosibirsk Research Institute of Traumatology and Orthopaedics was carrying out clinical trials of combined immunotherapy within complex therapy of patients with malignant brain glioma in compliance with two protocols.

scholarly journals Immunotherapy in endometrial cancer: rationale, practice and perspectives

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Wenyu Cao ◽  
Xinyue Ma ◽  
Jean Victoria Fischer ◽  
Chenggong Sun ◽  
Beihua Kong ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Endometrial Cancer ◽  
Cancer Vaccines ◽  
Molecular Basis ◽  
Checkpoint Inhibitors ◽  
Molecular Classification ◽  
Adoptive Cell Transfer ◽  
Immune Checkpoints ◽  
Effective Strategies ◽  
Tumor Research

AbstractTumor immunotherapy has attracted more and more attention nowadays, and multiple clinical trials have confirmed its effect in a variety of solid tumors. Immune checkpoint inhibitors (ICIs), cancer vaccines, adoptive cell transfer (ACT), and lymphocyte-promoting cytokines are the main immunotherapy methods. Endometrial cancer (EC) is one of the most frequent tumors in women and the prognosis of recurrent or metastatic EC is poor. Since molecular classification has been applied to EC, immunotherapy for different EC subtypes (especially POLE and MSI-H) has gradually attracted attention. In this review, we focus on the expression and molecular basis of the main biomarkers in the immunotherapy of EC firstly, as well as their clinical application significance and limitations. Blocking tumor immune checkpoints is one of the most effective strategies for cancer treatment in recent years, and has now become the focus in the field of tumor research and treatment. We summarized clinical date of planned and ongoing clinical trials and introduced other common immunotherapy methods in EC, such as cancer vaccine and ACT. Hormone aberrations, metabolic syndrome (MetS) and p53 mutant and that affect the immunotherapy of endometrial cancer will also be discussed in this review.

Sign in / Sign up

Export Citation Format

Share Document